<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of warfarin-associated bleeding or supratherapeutic INR</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of warfarin-associated bleeding or supratherapeutic INR</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of warfarin-associated bleeding or supratherapeutic INR</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell D Hull, MBBS, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David A Garcia, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> is associated with an increased risk of bleeding, as are a variety of other anticoagulants. The effect of warfarin has great inter- and intra-individual variation based on a variety of genetic, dietary, and medication effects.</p><p>This topic discusses risk factors for warfarin-associated bleeding and poor international normalized ratio (INR) control and presents an approach to the management of a patient with warfarin-associated bleeding or an INR above the therapeutic range (ie, a supratherapeutic INR).</p><p>The following special populations are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intracerebral hemorrhage</strong> – (See  <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heavy menstrual</strong> <strong>bleeding</strong> – (See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Patients on anticoagulant therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery/invasive procedure</strong> – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient with a prosthetic heart valve</strong> – (See  <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"</a>.)</p><p></p><p>A discussion of factors that affect <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> dosing and a review of warfarin administration and other complications are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a> and  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H624013"><span class="h1">MITIGATING BLEEDING RISK</span><span class="headingEndMark"> — </span>The risk of major bleeding in patients treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is related to the degree of anticoagulation as well as patient characteristics and comorbidities [<a href="#rid1">1-20</a>]. Importantly, some of these risk factors are modifiable, and addressing modifiable risk factors may ultimately reduce the risks of both bleeding and thrombosis. Even patients with a therapeutic INR can have an increased risk of bleeding, especially those older than 70 years of age [<a href="#rid21">21-23</a>]. A comprehensive discussion of risk factors and risk reduction is presented separately. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p>The INR above which bleeding risk increases further varies among studies. Studies in patients with atrial fibrillation indicate that the risk of bleeding increases substantially at INR values ≥5  (<a class="graphic graphic_figure graphicRef65373" href="/z/d/graphic/65373.html" rel="external">figure 1</a>), although other studies including those with other patient populations have shown an increased risk of bleeding when the INR is &gt;3.0 or 3.5  (<a class="graphic graphic_figure graphicRef78252" href="/z/d/graphic/78252.html" rel="external">figure 2</a>) [<a href="#rid24">24-26</a>]. Isolated supratherapeutic INR values in asymptomatic patients appear to be associated with a low risk of bleeding within 30 days, provided the <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> dose is adjusted promptly [<a href="#rid22">22</a>]. Factors that contribute to a supratherapeutic INR are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Risk factors for supratherapeutic INR'</a>.)</p><p>A number of bleeding risk scores have been developed and validated, mostly in patients receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for atrial fibrillation. However, these scores generally do not perform significantly better than clinician judgment based on close consideration of patient characteristics. Further details are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Bleeding risk scores'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">TREATMENT OF BLEEDING</span><span class="headingEndMark"> — </span>As a general rule, patients with serious or life-threatening bleeding require rapid, full reversal of any <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> effect, whereas those with no bleeding or minor bleeding may be best served by holding warfarin without administration of a reversal agent, especially if the underlying thrombotic risk is particularly high.</p><p class="headingAnchor" id="H744870"><span class="h2">Serious/life-threatening bleeding</span><span class="headingEndMark"> — </span>The following is appropriate for serious or life-threatening bleeding  (<a class="graphic graphic_table graphicRef119954" href="/z/d/graphic/119954.html" rel="external">table 1</a>) [<a href="#rid27">27-31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinue </strong><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> – Administer 10 mg vitamin K by slow intravenous infusion (eg, over 20 to 60 minutes). For most patients receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> who have severe, obvious bleeding, vitamin K can be administered without waiting for laboratory tests or imaging studies because the risks associated with vitamin K are low, and if the patient requires reinitiation of anticoagulation while refractory to warfarin, another agent such as heparin can be used. Vitamin K may be repeated at 12-hour intervals if the INR remains elevated. (See <a class="local">'Vitamin K dose, route, formulation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCC</strong> – For patients with serious bleeding and INR &gt;2, we suggest using a <a class="drug drug_general" data-topicid="9450" href="/z/d/drug information/9450.html" rel="external">4-factor prothrombin complex concentrate</a> (PCC, unactivated)  (<a class="graphic graphic_table graphicRef94210" href="/z/d/graphic/94210.html" rel="external">table 2</a>) rather than a 3-factor PCC and/or Fresh Frozen Plasma (FFP) for rapid reversal, due to the similar efficacy and lower risk of adverse events with 4-factor PCC.</p><p></p><p class="bulletIndent1">PCC can be administered using a fixed dose, as illustrated in the table  (<a class="graphic graphic_table graphicRef89478" href="/z/d/graphic/89478.html" rel="external">table 3</a>), or using a regimen that calculates the dose based on the patient's weight and the INR at presentation; a typical dose for INR &gt;6 is 50 units/kg [<a href="#rid32">32</a>]. We generally suggest a fixed dose for greater ease of use and faster treatment. Institutional protocols should be followed. (See <a class="local">'Dosing'</a> below.)</p><p></p><p class="bulletIndent1">Constituents of PCC products, evidence for efficacy, and thrombotic risks are presented below. (See <a class="local">'PCC products'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Recheck the prothrombin time (PT)/INR at approximately 30 minutes following PCC administration, and periodically thereafter, with the frequency determined by the severity of bleeding. Repeat dosing of PCC is generally not needed for individuals treated with a dose based on the patient's weight and INR; however, if bleeding is truly life-threatening and the INR remains elevated, a second dose may be reasonable. Consultation with an expert in anticoagulant management may be helpful. If a fixed dose regimen of 1000 or 2000 units was used and the INR remains elevated, a second dose may be required for full reversal. (See <a class="local">'PCC products'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other agents</strong> – Antifibrinolytic agents such as <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> or epsilon-aminocaproic acid may be used in some settings (eg, oral/mucosal bleeding). <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">Desmopressin</a> (DDAVP) may be used for platelet dysfunction. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Antifibrinolytics and other pro-hemostatic therapies'</a>.)</p><p></p><p class="bulletIndent1">Recombinant activated factor VII (rFVIIa) generally is not used to treat warfarin-associated bleeding, because it does not supply the other vitamin K-dependent factors affected by <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, although there are reports of its use [<a href="#rid33">33,34</a>]. Thromboembolic events after rFVIIa administration have been reported. (See  <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">"Recombinant factor VIIa: Administration and adverse effects", section on 'Thromboembolic complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Platelets</strong> – Platelet transfusion may be used if a patient is bleeding in the setting of thrombocytopenia. In the event of warfarin-associated major bleeding, some experts use a target platelet count of &gt;50,000/microL and others use a target platelet count of &gt;100,000/microL, especially for life-threatening bleeding. (See  <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Actively bleeding patient'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>RBCs</strong> – Transfusions of red blood cells (RBCs) are based on hemoglobin levels and/or estimated blood loss for rapid ongoing bleeding. (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Acute bleeding'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FFP</strong> – FFP may be given if no PCC is available (initial dose 15 to 30 mL/kg), or if the patient is receiving massive transfusions for severe ongoing bleeding (see  <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">"Massive blood transfusion"</a>). Doses of FFP required to replace coagulation factors often involve multiple units of FFP, which must be thawed and may take hours to administer, with risks of volume overload and transfusion reactions. (See  <a class="medical medical_review" href="/z/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction", section on 'Types of acute transfusion reactions'</a>.)</p><p></p><p>Additional considerations in patients with prosthetic heart valves or intracerebral bleeding are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a> and  <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Management of overanticoagulation without bleeding'</a>.)</p><p class="headingAnchor" id="H747097"><span class="h2">Urgent surgery/procedure</span><span class="headingEndMark"> — </span>On occasion, it is necessary to temporarily reverse anticoagulation for surgery or other invasive procedure. Management in this setting depends on the urgency and bleeding risk of the procedure and the rapidity with which reversal is required. The urgency of the procedure and necessity of reversing <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> should be determined in consultation with the surgeon/interventionist. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Deciding whether to interrupt anticoagulation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent</strong> – For those requiring urgent (eg, same day) reversal, we suggest administration of a 4-factor PCC with <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> as discussed in the preceding section. (See <a class="local">'Serious/life-threatening bleeding'</a> above.)</p><p></p><p class="bulletIndent1">For patients who can wait 24 hours before going to surgery, <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (dose 1 to 2 mg) will typically be sufficient to lower the INR; in such cases, PCC and FFP can be avoided. This calculation regarding the urgency of the required procedure should involve close consultation with the surgeon/interventionist.</p><p></p><p class="bulletIndent1">The greater efficacy and lower risk of volume overload of 4-factor PCC versus FFP in the setting of urgent surgery was demonstrated in an industry-funded trial that randomly assigned 181 patients who required an urgent procedure to receive either 4-factor PCC or FFP [<a href="#rid35">35</a>]. Doses were adjusted according to the INR; all patients received <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a>. Adequate hemostasis was achieved more frequently in those receiving 4-factor PCC (90 versus 75 percent), as was INR reduction within 30 minutes (55 versus 10 percent). Adverse events were similar in the two groups (56 versus 60 percent), thromboembolic complications were similar (7 versus 8 percent), and volume overload occurred less often with PCC (3 versus 13 percent). A post hoc analysis of data from this trial confirmed that use of FFP was independently associated with a greater risk of volume overload compared with use of a 4-factor PCC (odds ratio 2.74; 95% CI 1.21-6.19) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elective</strong> – Management of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> around the time of elective surgery is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures"</a>.) </p><p></p><p class="headingAnchor" id="H745238"><span class="h2">Minimal bleeding</span><span class="headingEndMark"> — </span>There is little guidance as to how patients with minimal bleeding in the setting of an elevated INR (eg, &gt;5) should be treated. Options include withholding <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, holding warfarin and giving <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a>, or more aggressive reversal as outlined for patients with more significant bleeding (see <a class="local">'Serious/life-threatening bleeding'</a> above). The choice among these approaches depends on the perceived likelihood of progression to more severe bleeding. The approach is based largely on clinical judgment that considers the extent and site of bleeding, previous bleeding, comorbidities such as renal insufficiency or hypertension, concomitant antiplatelet therapy, INR level, and likelihood that the INR may be rising, based on the percent of time the INR has been supratherapeutic over the previous few measurements [<a href="#rid21">21</a>]. As examples, a patient with a minor nosebleed in the setting of high thromboembolic risk may be treated with local measures, whereas a patient with bleeding from a site not easily accessed who has a lower thromboembolic risk and other comorbidities may require additional interventions.</p><p class="headingAnchor" id="H4009610211"><span class="h1">TREATMENT OF SUPRATHERAPEUTIC INR WITHOUT BLEEDING</span></p><p class="headingAnchor" id="H745327"><span class="h2">INR &gt;10 without bleeding</span><span class="headingEndMark"> — </span>If the INR is &gt;10 and the patient does not have clinically significant bleeding, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> should be held until the INR falls into the therapeutic range. <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> can be administered as an oral dose of 2.5 to 5 mg, depending on the bleeding risk of the patient [<a href="#rid31">31,37</a>]. Administration of vitamin K should produce a substantial reduction in the INR within 24 to 48 hours  (<a class="graphic graphic_table graphicRef119954" href="/z/d/graphic/119954.html" rel="external">table 1</a>) [<a href="#rid27">27,38</a>]. The INR should be monitored closely (eg, daily, every other day), and oral vitamin K may be repeated as necessary.</p><p>In a retrospective series of 809 individuals with INR &gt;10 and no bleeding, some of whom were treated with <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> and some not, there was no statistically significant difference in the rate of bleeding or thrombosis at 30 days or in the time it took for the INR to drop below 4 (on average, slightly over 2 days) [<a href="#rid39">39</a>]. Approximately 10 percent of the no vitamin K group received vitamin K more than a day later, but exclusion of their data did not appreciably change the results.</p><p>A reduced maintenance dose of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> generally should be restarted when the INR falls into the therapeutic range.</p><p>Nonbleeding patients should not be given prothrombin complex concentrate (PCC) or Fresh Frozen Plasma (FFP) solely to correct a supratherapeutic INR as these products have associated risks (eg, thrombosis, transfusion reactions) (see <a class="local">'PCC products'</a> below) and there is not clear evidence of benefit. For nonbleeding patients, there is no clear benefit to giving larger doses of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> or to giving vitamin K by the intravenous route (unless the patient cannot take an oral medication). Patients who receive higher doses of vitamin K may have a prolonged period in which the INR cannot be raised, and intravenous administration is associated with a small risk of anaphylaxis, especially when given rapidly [<a href="#rid40">40-43</a>].</p><p class="headingAnchor" id="H8"><span class="h2">INR 4.5 to 10 without bleeding</span><span class="headingEndMark"> — </span>If the INR is between 4.5 and 10 and the patient does not have clinically significant bleeding, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is held temporarily (eg, one or two doses), with or without administration of a small dose of oral <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (1 to 2.5 mg)  (<a class="graphic graphic_table graphicRef119954" href="/z/d/graphic/119954.html" rel="external">table 1</a>). As discussed below, evidence suggests that vitamin K does not reduce bleeding complications in this setting. The 2012 American College of Chest Physicians and the 2018 American Society of Hematology (ASH) guidelines both have a suggestion not to use vitamin K in this setting, although the 2012 ACCP guideline offers low dose oral vitamin K as an option [<a href="#rid22">22,31,37</a>]. (See <a class="local">'ACCP and ASH guidelines'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>We generally favor the administration of a low dose of oral <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> for individuals with a greater risk of bleeding (eg, older, prior bleeding) and a lower risk of thromboembolism. We also have a low threshold for giving vitamin K to patients with conditions known to slow the spontaneous lowering of a supratherapeutic INR such as decompensated heart failure or active malignancy. These risk factors were identified in a retrospective record review of 633 patients with INR &gt;6, in which the following predicted for a supratherapeutic INR two days after stopping <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid44">44</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older age (odds ratio [OR] 1.2 per decade of life)</p><p class="bulletIndent2"><span class="glyph">•</span>Higher index INR (OR 1.25 per unit of elevation)</p><p class="bulletIndent2"><span class="glyph">•</span>Lower <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> maintenance dose (OR 0.87 per 10 mg increase in total weekly dose)</p><p class="bulletIndent2"><span class="glyph">•</span>Decompensated heart failure (OR 2.79; 95% CI 1.30-5.98)</p><p class="bulletIndent2"><span class="glyph">•</span>Active cancer (OR 2.48; 95% CI 1.11-5.57)</p><p></p><p class="bulletIndent1">Other factors such as lack of rapid access to medical care may also contribute to the decision regarding <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> administration. Patients should be instructed to report and/or seek prompt medical attention for any signs of bleeding (eg, headache, melena, cardiovascular symptoms) or thromboembolism.</p><p></p><p class="bulletIndent1">It has been suggested that small oral doses of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> may be given by administering the intravenous preparation (2 mg/mL) orally, because pills may be difficult to cut [<a href="#rid45">45-47</a>]. (See <a class="local">'Vitamin K dose, route, formulation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally favor holding the <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonist without giving vitamin K for individuals with a low risk of bleeding and those who may have a more rapid return of the INR to the therapeutic range, such as the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – Children metabolize <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> more rapidly than adults. In a series of 89 children with supratherapeutic INR (mean INR, 5.9) who did not receive <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a>, the next day repeat was below 5 in 89 percent (mean INR, 3.3) [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9159" href="/z/d/drug information/9159.html" rel="external">Acenocoumarol</a> – Acenocoumarol has a shorter half-life than <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. Two small trials that randomly assigned a total of 169 acenocoumarol-treated patients with a supratherapeutic INR to receive <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> versus placebo along with omitting the acenocoumarol dose both found that omitting the dose without giving supplemental vitamin K was associated with similar time to return of the INR to the therapeutic range and less risk of a subtherapeutic INR [<a href="#rid49">49-51</a>].</p><p></p><p>The INR should be monitored more frequently during the period of observation and <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> reinitiation (eg, every 24 to 72 hours until warfarin is resumed). When warfarin is restarted, a lower maintenance dose is likely to be appropriate unless a transient cause of the supratherapeutic INR has been identified and corrected. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Initial dosing'</a>.)</p><p>The similar efficacy and safety of holding <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> with or without giving <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> for this degree of INR elevation was documented in a 2019 meta-analysis [<a href="#rid52">52</a>]. Examples of illustrative trials include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter trial that randomly assigned 724 patients with INR between 4.5 and 10 without bleeding to receive <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (1.25 mg orally) or placebo, outcomes were similar in both arms [<a href="#rid22">22</a>]. All patients had their <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> dose held.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bleeding was seen with equal frequency in both the <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> and placebo groups (16 versus 16 percent cumulative rates at 90 days), although the INR decreased more rapidly in the vitamin K group (mean decrease on the day after treatment, 2.8 versus 1.4; decrease into the therapeutic range on the day after treatment, 42 versus 10 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There were no significant differences in mortality (2 percent in both groups), bleeding at one month (12 versus 13 percent), and thromboembolic events (1 percent in both groups). There was a trend towards more major bleeding events in the <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> group that did not reach statistical significance (9 versus 4 patients; 2.5 versus 1.1 percent; respectively). Outcomes were unaffected by patient age or INR, although most of the major bleeding (10 of 13 events) occurred in patients older than 70 years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a smaller trial that randomly assigned 92 patients with INR between 4.5 and 10 without bleeding to receive <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (1 mg orally) or placebo, a therapeutic INR on the day after treatment was more likely in the vitamin K group (56 versus 20 percent) [<a href="#rid40">40</a>]. Bleeding at 30 days was less frequent in the vitamin K group (two versus eight events). However, the likelihood of overcorrection (subtherapeutic INR on the day after treatment) was also greater with vitamin K (16 versus 0 percent), although subsequent INRs were similar (ie, there was no delay in re-anticoagulation). There was one thrombotic event in each group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, investigators randomly assigned 59 patients with a prosthetic heart valve and INR between 6 and 12 to receive <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (1 mg orally) or no treatment [<a href="#rid53">53</a>]. There were no major bleeding events; INR correction was more rapid with vitamin K (mean INR on the day after treatment: 3 versus 5).</p><p></p><p>Patients who receive higher doses of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> may have a prolonged period in which the INR cannot be raised, and intravenous administration is associated with a small risk of anaphylaxis, especially when given rapidly [<a href="#rid40">40-43</a>].</p><p>Nonbleeding patients also should not be given FFP or other PCCs solely to correct a supratherapeutic INR, as these products have risks (eg, transfusion reactions, thromboembolic events) and no clear benefit from their administration has been demonstrated in this setting [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H745479"><span class="h2">INR &lt;4.5 without bleeding</span><span class="headingEndMark"> — </span>If the INR is above the therapeutic range but &lt;4.5 and no clinically significant bleeding is apparent, the next dose of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> should be omitted and/or the maintenance dose of warfarin reduced slightly  (<a class="graphic graphic_table graphicRef119954" href="/z/d/graphic/119954.html" rel="external">table 1</a>) [<a href="#rid31">31,37</a>]. Often, the maintenance dose does not need to be reduced at all, especially if the INR elevation is minimal and/or expected to be transient [<a href="#rid55">55</a>]. Additional therapies such as <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> are not indicated in this setting. Increased monitoring (eg, INR testing once or twice a week) during the period of dose adjustment is appropriate.</p><p class="headingAnchor" id="H745933"><span class="h1">SUPERWARFARIN POISONING</span><span class="headingEndMark"> — </span>The "superwarfarins" (eg, brodifacoum, bromadiolone, coumafuryl, difenacoum) are used as rat poisons (rodenticides); these lipophilic, long-acting agents are up to 100 times as potent as <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. They have half-lives within the body of weeks to months compared with hours to days for clinically used <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonists [<a href="#rid56">56-58</a>].</p><p>Poisoning with superwarfarins has been due to accidental exposure, suicide attempts, or occupational exposure. Individuals may also be exposed when drugs of abuse (eg, marijuana, synthetic cannabinoids, crack cocaine) are combined ("laced") with superwarfarins, presumably to potentiate their effect [<a href="#rid59">59-61</a>]. The diagnosis is confirmed when specific assays for the superwarfarin molecule are performed [<a href="#rid62">62</a>]. However, this testing may involve significant delays, and management must be made based on the clinical history and results of coagulation testing pending results of superwarfarin testing. Additional details of the evaluation for superwarfarin poisoning are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/100310.html" rel="external">"Anticoagulant rodenticide poisoning: Clinical manifestations and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">"Synthetic cannabinoids: Acute intoxication", section on 'Life-threatening coagulopathy (brodifacoum adulteration)'</a>.)</p><p>Individuals poisoned with one of the superwarfarins can develop a severe, long-lasting coagulopathy and may have bleeding associated with a prolonged PT, activated partial thromboplastin time (aPTT), and INR; these individuals usually require massive doses of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (eg, 50 to 800 mg per day) given orally over extended periods of time up to months to years [<a href="#rid56">56-58,62,63</a>]. Repeated assays for the superwarfarin and/or coagulation testing may be helpful in determining the duration of vitamin K treatment required [<a href="#rid57">57,63</a>].</p><p class="headingAnchor" id="H428500"><span class="h1">PCC PRODUCTS</span><span class="headingEndMark"> — </span>All centers that treat patients with warfarin-associated bleeding should stock a prothrombin complex concentrate (PCC) for rapid reversal when needed. When available, a 4-factor PCC is the preferred agent for the acute reversal of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation. </p><p>However, PCC products may be unavailable in some institutions, and their high cost poses a serious barrier to their use [<a href="#rid64">64</a>]. If a 4-factor PCC is unavailable, a 3-factor PCC can be given; this is often supplemented with a plasma product such as Fresh Frozen Plasma (FFP) to provide a source of factor VII, which is present in low/insufficient amounts in 3-factor PCC products [<a href="#rid65">65</a>]. </p><p class="headingAnchor" id="H2521965538"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>Dosing units are based on units of factor IX activity. Dosing can be by fixed dose  (<a class="graphic graphic_table graphicRef89478" href="/z/d/graphic/89478.html" rel="external">table 3</a>) or calculated based on the patient's weight and INR at presentation. </p><p>We generally suggest a fixed dosing regimen, since it is easier to use and may result in faster treatment. Additional doses can be provided if needed for individuals with higher-than average weight or if the INR does not decrease sufficiently. Institutions should determine their own protocols and make these available to clinicians for maximum ease of use. An institutional set of reversal guidelines that specify dosing and monitoring based on locally available products can be of great value in guiding the clinician in treating patients with significant bleeding. Such institutional plans can be updated iteratively based on local experience and can incorporate simplified dosing based on patient weight and INR when appropriate [<a href="#rid28">28</a>]. </p><p>Evidence to support fixed versus weight-based dosing is limited. A randomized trial in 199 adults who presented with major extracranial bleeding associated with a <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonist compared fixed dose 4-factor PCC (1000 units) versus weight-based dosing (calculated from weight and INR) [<a href="#rid66">66</a>]. Effective hemostasis (determined by blinded clinicians) was seen in 74 of 84 fixed dose patients (88 percent) and 76 of 85 weight-based dose patients (89 percent). Effective INR lowering and other outcomes were also similar between groups. Door-to-needle times were shorter in the fixed dose arm (median time 109 versus 142 minutes; difference, 33 minutes; 95% CI 56-4 minutes), and initial PCC dose was lower in the fixed dose arm (1000 units, versus 1750 units with weight-based dosing). To avoid delays, treating clinicians were not blinded, and the trial was closed early due to low accrual; however, these results are reassuring that fixed dosing is a reasonable approach.</p><p>Repeat dosing may be required if a fixed dose regimen of 1000 or 2000 units was used and the INR remains elevated. If a regimen titrated to patient weight and INR is used, a second dose is rarely needed but might be used if the INR remains elevated and life-threatening (eg, intracranial) bleeding is being treated. (See <a class="local">'Serious/life-threatening bleeding'</a> above.)</p><p>It is important to be aware of which PCC products are locally available and recommended by institution-specific protocols  (<a class="graphic graphic_table graphicRef94210" href="/z/d/graphic/94210.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>4-factor PCC</strong> – 4-factor PCCs (eg, Beriplex [available as Kcentra in the United States], Octaplex [available as Balfaxar in the United States], Confidex [available in Europe]) contain all of the vitamin K-dependent coagulation factors (ie, factors II, VII, IX, and X) in an unactivated form [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>3-factor PCC</strong> – 3-factor PCC (eg, Profilnine) contains only factors II, IX, and X, in an unactivated form. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activated PCC</strong> – Activated PCC (aPCC) contains factors II, VII, IX, and X; factor VII is mostly present in the activated form, which is potentially more prothrombotic. The only aPCC available in the United States is Factor Eight Inhibitor Bypassing Activity (FEIBA). FEIBA generally is <strong>not </strong>used for reversing <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation, based on theoretical concerns that the activated factor VII in FEIBA is potentially more prothrombotic than the unactivated factors in unactivated PCC. For warfarin, an activated factor is not needed to "bypass" any inhibitory activity in the patient's coagulation system (as occurs with some other anticoagulants). Differences between various PCC products are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">"Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'PCCs'</a>.)</p><p></p><p class="headingAnchor" id="H3867998934"><span class="h2">Evidence for efficacy</span><span class="headingEndMark"> — </span>Advantages of PCC over FFP include the rapidity of administration and INR reversal, and the small volume in which factors can be administered. PCC are preferred over FFP because they raise the activity levels of the depleted factors very quickly without risks associated with FFP such as volume overload and transfusion-related acute lung injury (TRALI).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCC versus FFP</strong> – Evidence that 4-factor PCCs are at least as effective as FFP comes from a trial that randomly assigned 216 patients with major warfarin-associated bleeding to receive a 4-factor PCC or FFP; all were given intravenous <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> [<a href="#rid68">68</a>]. PCC and FFP provided similar hemostasis (72 versus 65 percent) and similar length of hospital stay (median 4.5 versus 4.2 days). There were more deaths in the PCC group (mortality in 10 versus 5 percent); however, when only deaths considered to be related to the therapy were compared, mortality was seen in only 1 versus 0 percent (according to the Safety Adjudication Board) or 0 versus 0 percent (according to the investigators). Adverse events related to the study drug were seen in 2 versus 4 percent with PCC versus FFP; fluid overload was more common in those given FFP. A 2022 network meta-analysis of randomized trials (594 participants in total) found that PCCs had a higher rate of INR reversal and in some comparisons a higher rate of bleed cessation [<a href="#rid69">69</a>]. </p><p></p><p class="bulletIndent1">Similar results were seen in patients requiring urgent surgery, for whom 4-factor PCC resulted in faster INR correction and fewer episodes of volume overload compared with FFP. (See <a class="local">'Urgent surgery/procedure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>4-factor versus 3-factor PCC</strong> – A 4-factor product has not been compared with a 3-factor product in a randomized controlled trial. </p><p></p><p class="bulletIndent1">It is difficult to draw strong conclusions based on observational data, especially in studies in which administration was not contemporaneous [<a href="#rid70">70</a>]. Contributing factors to better outcomes in patients treated with 4-factor PCC may include avoidance of rFVIIa, which has known prothrombotic risks; lower doses of the 4-factor product than the 3-factor product in some cases (25 units/kg versus 50 units/kg for INRs between 2 and 4); general advances in care during the period of time when the 4-factor product became available; and greater resource availability and/or hemostasis/thrombosis expertise in facilities that stock 4-factor PCCs. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>4-factor PCC versus FEIBA</strong> – FEIBA is generally not used for warfarin-associated bleeding due to a greater thrombotic risk and no need to bypass a factor inhibitor. There is a lack of high-quality data on the safety of FEIBA for warfarin-associated bleeding, and no randomized trials have directly compared FEIBA with unactivated PCC in this setting. In a retrospective observational study involving 342 individuals with warfarin-associated intracerebral hemorrhage (ICH) who were treated with a 4-factor PCC or FEIBA, those receiving 4-factor PCC were more likely to have improvement in the prothrombin time (PT)/INR to ≤1.5 [<a href="#rid71">71</a>]. </p><p></p><p>Several smaller earlier series also reported administration of 4-factor PCC for <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonist reversal and found rapid normalization of the INR (eg, within 30 minutes) without thromboembolic complications or additional bleeding [<a href="#rid72">72-74</a>].</p><p>Evidence for fixed versus weight-based dosing is discussed above. (See <a class="local">'Dosing'</a> above.)</p><p class="headingAnchor" id="H3559957624"><span class="h2">PCC risks</span><span class="headingEndMark"> — </span>As noted above, PCC carries a small but real prothrombotic risk. This risk was estimated from a 2011 meta-analysis of 27 observational studies that included 1032 patients treated with PCCs for bleeding or urgent surgery in the setting of a <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonist [<a href="#rid75">75</a>]. Twelve patients had a thromboembolic complication (1.4 percent), two of which were fatal. A single institution observational study of persons with warfarin-associated ICH suggests the short-term risk of venous thromboembolism after PCC administration may be particularly high in patients with a prior history of venous thrombosis [<a href="#rid76">76</a>]. Thus, PCC should only be used for individuals who require rapid <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> reversal.</p><p>Another series published in 2016 (after the meta-analysis) included 113 consecutive patients who received 4-factor PCC for <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonist reversal in the setting of bleeding or emergency surgery [<a href="#rid77">77</a>]. Approximately one-third of the patients in this series were at a higher risk of thrombosis due to conditions such as sepsis or antiphospholipid syndrome (APS). There were seven thromboembolic complications (6 percent), two of which (1.8 percent) occurred within three days of PCC administration and thus were deemed potentially related to the PCC (one ischemic stroke in a patient on a left ventricular assist device [LVAD] and one abdominal ischemic event in a patient with APS and sepsis). There were 17 deaths, including the two patients with PCC-related events (from hemorrhagic transformation and sepsis, respectively).</p><p>Some PCC products contain heparin, and these should not be used in individuals with a history of heparin-induced thrombocytopenia (HIT).</p><p class="headingAnchor" id="H21790898"><span class="h1">VITAMIN K DOSE, ROUTE, FORMULATION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> is appropriate for warfarin-treated individuals with serious/life-threatening bleeding and for some individuals with a supratherapeutic INR, as discussed above. (See <a class="local">'Treatment of bleeding'</a> above.)</p><p><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> administration should occur promptly when indicated. However, reversal of the <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> effect may take several hours to fully occur because it depends on new synthesis of coagulation factors in the liver. Thus, for serious/life-threatening bleeding, administration of clotting factors (either as prothrombin complex concentrates [PCCs] or Fresh Frozen Plasma [FFP]) is paramount; PCCs can correct a supratherapeutic INR within 30 minutes.</p><p><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> can be administered intravenously or orally for patients receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>; intramuscular and subcutaneous routes of administration are not appropriate for reversing anticoagulation. The dose and route of vitamin K depends on the severity of bleeding [<a href="#rid42">42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with major bleeding generally are given 10 mg of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> by slow intravenous infusion (eg, over 20 to 60 minutes). (See <a class="local">'Serious/life-threatening bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with a supratherapeutic INR without bleeding for whom <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> is clinically appropriate generally are given lower doses of oral vitamin K because oral administration is effective within one to two days and eliminates the small risk of anaphylaxis with intravenous use. Use of excessive doses of vitamin K should be avoided, especially for individuals who do not have bleeding, because the effect can last for several days (or even weeks). (See <a class="local">'INR &gt;10 without bleeding'</a> above and <a class="local">'INR 4.5 to 10 without bleeding'</a> above.)</p><p></p><p><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> dosing can be repeated at approximately 12-hour intervals if needed based on the criteria outlined above (see <a class="local">'Treatment of bleeding'</a> above). A requirement for more than one or two days should raise the possibility of superwarfarin poisoning or impaired absorption of an oral preparation. (See <a class="local">'Superwarfarin poisoning'</a> above.)</p><p>A meta-analysis of 10 randomized and 11 prospective trials evaluated the relative effectiveness of the various routes of <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> administration in patients with an INR of 4 to 10 without bleeding. At 24 hours after stopping <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, the percentages of patients with an INR in the range of 1.8 to 4.0 were as follows [<a href="#rid78">78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Placebo – 20 percent (95% CI 0-47)</p><p class="bulletIndent1"><span class="glyph">●</span>Subcutaneous <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> – 31 percent (95% CI 7-55)</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> – 77 percent (95% CI 60-95)</p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> – 82 percent (95% CI 70-93)</p><p></p><p>The authors concluded that the subcutaneous route for <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> was no better for this purpose than placebo and should not be employed. This analysis was unable to determine the optimal dose of vitamin K; effective doses ranged from 1 to 2.5 and 0.5 to 3 mg for the oral and intravenous routes, respectively. Given the size of vitamin K tablets available in the United States (5 mg, scored to allow administration of 2.5 mg), it has been suggested that a 1 mg oral dose is most reliably given by administering 1 mg of the intravenous preparation (2 mg/mL) by mouth [<a href="#rid45">45</a>].</p><p>Vitamin K represents a family of structurally similar compounds required for the synthesis of vitamin K-dependent clotting factors. Commercially available preparations include vitamin K1 (<a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">phytonadione</a>, the form produced by plants), K2 (menaquinone, the form synthesized by bacteria and mitochondria, and the main storage form in humans), and other synthetic forms [<a href="#rid79">79,80</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin K1</strong> – Most of the clinical trials that have studied <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> administration for <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> reversal have used vitamin K1. This is the most commonly available formulation in the United States. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin K2</strong> – Vitamin K2 is commonly used in Japan [<a href="#rid81">81</a>].</p><p></p><p>Since both vitamin K1 and K2 are effective in reversing coagulopathy, we favor whichever formulation is most readily available. (See  <a class="medical medical_review" href="/z/d/html/1318.html" rel="external">"Vitamin K-dependent clotting factors: Gamma carboxylation and functions of Gla"</a> and  <a class="medical medical_review" href="/z/d/html/2624.html" rel="external">"Overview of vitamin K"</a>.)</p><p class="headingAnchor" id="H742246"><span class="h1">ADDITIONAL EVALUATIONS</span></p><p class="headingAnchor" id="H38425347"><span class="h2">Other explanations for bleeding or high INR</span><span class="headingEndMark"> — </span>Not all bleeding (or bleeding risk) is due to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. In some cases, an anatomic lesion (eg, tumor, arteriovenous malformation) may contribute to bleeding or may be revealed in the setting of anticoagulant administration, especially gastrointestinal bleeding or hematuria [<a href="#rid80">80</a>]. Many patients will require additional evaluation for such lesions in the setting of warfarin anticoagulation and/or warfarin-associated bleeding as discussed in the sections below.</p><p>In addition, individuals with a supratherapeutic INR should also be evaluated for possible medication errors or other factors that might lead to excessive anticoagulation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Correct dosing</strong> – The patient should be asked about the number of pills and their physical description (eg, color) and whether the prescription has been recently changed or renewed. When possible, the pills should be examined to make sure that the proper dose of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> was being taken. Factors that may interfere with medication adherence are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Medication adherence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic changes</strong> – The patient should be asked about new medications, over the counter remedies, symptoms that may affect absorption (decreased intake, diarrhea), and recent dietary changes. (See  <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control", section on 'Overview of INR control'</a>.)</p><p></p><p>Additional interventions for labile INRs that cannot be explained by these factors (eg, low-dose <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> supplementation, changing to another anticoagulant) are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Establishing a maintenance dose'</a>.)</p><p class="headingAnchor" id="H742416"><span class="h2">Mild head trauma</span><span class="headingEndMark"> — </span>Intracerebral bleeding in an anticoagulated patient, either spontaneous or trauma-induced, is a <strong>medical emergency</strong> that requires immediate treatment (see  <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>). However, some anticoagulated patients with intracerebral bleeding do not have focal neurologic symptoms, and some patients with neurologic symptoms may have an ischemic event (eg, thromboembolic stroke related to atrial fibrillation). Thus, it is important to evaluate individuals with potential central nervous system bleeding using imaging studies.</p><p>For any individual receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (or any anticoagulant) who presents to the emergency department with head trauma, neuroimaging should be performed during the emergency assessment regardless of the presence of neurologic symptoms or the severity of the trauma. Non-contrast computed tomography (CT) or magnetic resonance imaging (MRI) can be used, as long as there is not a substantial delay. This practice is supported by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review of 215,785 patients seen in two emergency departments identified 144 individuals who were taking <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, experienced head trauma, lacked new neurologic defects or other risk factors, and were evaluated with a CT scan [<a href="#rid82">82</a>]. Most were elderly women taking warfarin for atrial fibrillation who had fallen. Of these, 10 had clinically important injuries (7 percent) including parenchymal, subdural, and subarachnoid hemorrhages. One had an acute ischemic stroke.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review at a trauma center identified 105 patients receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> who experienced mild head trauma and had a normal neurologic examination [<a href="#rid83">83</a>]. Of these, 26 (25 percent) had evidence of intracranial bleeding. No clinical finding could reliably predict the findings on neuroimaging, including mechanism of injury, fracture, loss of consciousness, or INR.</p><p></p><p>A discussion of typical clinical and radiographic findings in patients with anticoagulant-associated intracerebral hemorrhage is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Management of patients with head trauma and negative neuroimaging should be individualized. The intensities of monitoring and reversal of anticoagulation depend upon the degree of anticoagulation, the underlying indication, and the clinical findings. As examples, for a patient with atrial fibrillation and a low thromboembolic risk (eg, CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 2 (<a class="calc calc_professional" href="/z/d/html/99815.html" rel="external">calculator 1</a>)) who fell a large distance and has an INR of 4, the risk-benefit analysis may favor <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> administration. In contrast, for a patient with a recent pulmonary embolism (&lt;1 month), a minor fall, and an INR of 2, the risk-benefit analysis may favor close observation without <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> reversal, with rapid access to reversal should it be needed.</p><p class="headingAnchor" id="H745669"><span class="h2">Gastrointestinal bleeding</span><span class="headingEndMark"> — </span>For a patient receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> who has gastrointestinal bleeding, endoscopy can be both diagnostic and therapeutic. Bleeding should not be attributed solely to anticoagulation, and the source of bleeding should be pursued as done for patients not receiving an anticoagulant. Details of the evaluation are presented separately according to the age of the patient and the acuity of bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Child, acute bleeding</strong> – (See  <a class="medical medical_review" href="/z/d/html/5857.html" rel="external">"Approach to upper gastrointestinal bleeding in children"</a> and  <a class="medical medical_review" href="/z/d/html/5904.html" rel="external">"Lower gastrointestinal bleeding in children: Causes and diagnostic approach"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adult, acute bleeding</strong> – (See  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occult bleeding</strong> (eg, positive fecal occult blood test or iron deficiency anemia without visible blood loss) – (See  <a class="medical medical_review" href="/z/d/html/2544.html" rel="external">"Evaluation of occult gastrointestinal bleeding"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected small bowel bleeding</strong> (eg, bleeding despite an obvious etiology from upper endoscopy and colonoscopy) – (See  <a class="medical medical_review" href="/z/d/html/2625.html" rel="external">"Evaluation of suspected small bowel bleeding (formerly obscure gastrointestinal bleeding)"</a>.)</p><p></p><p class="headingAnchor" id="H1831101823"><span class="h2">Heavy menstrual bleeding</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Patients on anticoagulant therapy'</a>.)</p><p class="headingAnchor" id="H745675"><span class="h2">Hematuria</span><span class="headingEndMark"> — </span>Hematuria in an anticoagulated patient is likely to be due to factors other than the anticoagulation (eg, anatomic lesion, infection) and it is important to evaluate the underlying cause of hematuria rather than to ascribe it merely to anticoagulation.</p><p>This was demonstrated in a prospective study of 243 patients treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> who were followed for two years with serial urinalysis [<a href="#rid84">84</a>]. Microscopic hematuria (≥5 red blood cells) was seen at least once in 69 of these individuals (28 percent); the majority of episodes were associated with a urinary tract infection that responded to antibiotic therapy. Of the 32 who had at least two episodes of hematuria without an obvious infection, an anatomic or infectious source was found in 27 (84 percent), including bladder cancer, nephrolithiasis, a cyst, or infection. Of interest, the incidence of hematuria and likelihood of finding a genitourinary source was similar to a control group not receiving anticoagulation. Other studies have reported similar findings and noted a greater increase in the prevalence of hematuria when the anticoagulant is combined with an antiplatelet agent [<a href="#rid85">85</a>].</p><p>In some cases, hematuria may be accompanied by a decline in renal function (referred to as "warfarin-related nephropathy" or "anticoagulant-related nephropathy"). This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/91030.html" rel="external">"Anticoagulant-related nephropathy"</a>.)</p><p>Details of the evaluation of hematuria (eg, urine culture, renal imaging) are also presented separately. (See  <a class="medical medical_review" href="/z/d/html/6089.html" rel="external">"Evaluation of microscopic hematuria in children"</a> and  <a class="medical medical_review" href="/z/d/html/6108.html" rel="external">"Evaluation of gross hematuria in children"</a> and  <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">"Etiology and evaluation of hematuria in adults"</a>.)</p><p class="headingAnchor" id="H746284"><span class="h2">Unknown bleeding source</span><span class="headingEndMark"> — </span>For patients who have evidence of bleeding (eg, acute decline in hemoglobin level) but for whom the site of bleeding is not obvious, it may be appropriate to evaluate the possibility of bleeding into a retroperitoneal or deep muscle site, as these may not always be apparent on the initial physical examination.</p><p class="headingAnchor" id="H746817"><span class="h1">RESUMPTION OF ANTICOAGULATION AFTER BLEEDING</span><span class="headingEndMark"> — </span>The decision regarding whether to resume anticoagulation depends on the patient's underlying thromboembolic risk and the estimated risk of rebleeding. As an example, a clearly reversible cause that is not likely to recur (eg, trauma) may favor resumption of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. In contrast, an unexplained INR variability in a patient taking warfarin appropriately may favor changing to another oral anticoagulant, and a new comorbidity or inability to take an oral anticoagulant appropriately may favor permanent discontinuation.</p><p>The risk of thrombosis and need for ongoing anticoagulation depends on the underlying condition, as discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'High recurrence risk'</a>.)</p><p>A significant number of patients are able to resume <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> safely, and the risk-benefit calculation may favor this practice as illustrated by the following series:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intracerebral</strong> – A retrospective cohort study compared outcomes in 719 patients who experienced an intracerebral hemorrhage (ICH) and survived the acute hospitalization; 172 (24 percent) resumed a <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> antagonist (median, 30 days after bleeding), and 547 did not [<a href="#rid86">86</a>]. The median age was 74 years, and three-quarters had atrial fibrillation (mean CHADS<sub>2</sub> score, 2.6). Compared with individuals who did not resume anticoagulation, those who resumed anticoagulation had a decreased risk of ischemic stroke at one year (3.9 versus 12.7 per 100 patient-years) and no increase in recurrent ICH (3.9 per 100 patient-years for both groups). Survival was also better in those who resumed anticoagulation (92 versus 62 percent); however, patients who restarted their anticoagulant were younger and had better functional status at hospital discharge.</p><p></p><p class="bulletIndent1">A discussion of anticoagulant resumption following ICH is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/129071.html" rel="external">"Spontaneous intracerebral hemorrhage: Secondary prevention and long-term prognosis", section on 'Anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal</strong> – A retrospective cohort study compared outcomes in 442 patients who experienced a gastrointestinal bleed while on <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>; 260 (59 percent) resumed warfarin (median, four days after bleeding) or never stopped it (41 patients; 9 percent), and 182 did not [<a href="#rid87">87</a>]. The median age was 74, and half of patients had used <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in the 90 days preceding the bleed. Compared with individuals who did not resume warfarin, those who resumed warfarin had a decreased risk of thromboembolic complications during 90 days of observation (0.4 versus 5.5 percent, which included three fatal ischemic strokes; hazard ratio [HR] 0.05; 95% CI 0.0-0.6). There was a trend toward increased bleeding that was not statistically significant (10 versus 5.5 percent; HR 1.32; 95% CI 0.5-3.6). Although five of the index bleeds were fatal, none of the recurrent bleeds were fatal. Warfarin resumption was associated with better survival (HR 0.31; 95% CI 0.2-0.6); however, this may reflect overall better clinical status despite the use of multivariable analysis adjusted for comorbidities.</p><p></p><p class="bulletIndent1">The optimal timing for anticoagulant resumption following gastrointestinal bleeding is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2609.html" rel="external">"Management of anticoagulants in patients undergoing endoscopic procedures", section on 'Resuming anticoagulants after hemostasis'</a>.)</p><p></p><p>Additional factors may influence the decision to reinitiate anticoagulation with an agent other than <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (eg, a direct oral anticoagulant [DOAC] such as <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a>, or <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>). Overall, DOACs are reported to confer a lower risk of major bleeding than warfarin, including ICH. Although all DOACs appear to cause <strong>less</strong> intracranial bleeding than warfarin, some DOACs cause <strong>more</strong> gastrointestinal bleeding than warfarin. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Comparison with heparin and warfarin'</a>.)</p><p>Additional evidence from series that include individuals receiving DOACs further supports the potential benefits of anticoagulant re-initiation. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Resumption of anticoagulation'</a>.)</p><p>Bleeding risk with these agents and differences that may affect choice of anticoagulant are presented separately. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H9418662"><span class="h1">ACCP AND ASH GUIDELINES</span><span class="headingEndMark"> — </span>Recommendations presented here are consistent with the 2018 American Society of Hematology (ASH) Guidelines and 2012 American College of Chest Physicians (ACCP) clinical practice guidelines  (<a class="graphic graphic_table graphicRef119954" href="/z/d/graphic/119954.html" rel="external">table 1</a>) [<a href="#rid27">27,31,37</a>].</p><p class="headingAnchor" id="H3315967380"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/689.html" rel="external">"Patient education: Warfarin (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk reduction</strong> – The greatest risk of bleeding generally occurs during initial treatment and with international normalized ratio (INR) instability. Bleeding risk is increased by liver disease, kidney disease, heart failure, older age, prior hemorrhage, and concomitant nonsteroidal anti-inflammatory drug [NSAID] use). Major bleeding rates in randomized trials are 1 to 3 percent per person-year. (See <a class="local">'Mitigating bleeding risk'</a> above and  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The optimal approach depends on bleeding, degree of INR elevation, and underlying thrombotic risk  (<a class="graphic graphic_table graphicRef119954" href="/z/d/graphic/119954.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serious bleeding, INR &gt;2.0</strong> – <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> should be withheld, <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (10 mg) given by slow intravenous infusion, and a rapid reversal agent given. We suggest <a class="drug drug_general" data-topicid="9450" href="/z/d/drug information/9450.html" rel="external">4-factor prothrombin complex concentrate</a> (PCC)  (<a class="graphic graphic_table graphicRef94210" href="/z/d/graphic/94210.html" rel="external">table 2</a>) rather than a 3-factor PCC or Fresh Frozen Plasma (FFP) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). If 4-factor PCC is not available, a 3-factor PCC supplemented with FFP or FFP alone is appropriate. For most cases, we suggest a fixed dosing regimen rather than dosing calculated based on weight or INR (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>); this facilitates ease of use and faster treatment. Institution-specific guidelines should be followed, and additional doses of PCC may be given if needed.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> can be repeated every 12 hours if needed. (See <a class="local">'Serious/life-threatening bleeding'</a> above and <a class="local">'PCC products'</a> above.)</p><p></p><p class="bulletIndent2">Reversal in intracerebral hemorrhage is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgery, INR &gt;2.0</strong> – Bleeding risk, need to reverse anticoagulation, and urgency of the procedure should be determined in consultation with the interventionist. (See <a class="local">'Urgent surgery/procedure'</a> above and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Deciding whether to interrupt anticoagulation'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Same day surgery required</strong> – <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> should be held, <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> given, and a rapid reversal agent given. We suggest a 4-factor PCC rather than FFP (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Can wait 24 hours</strong> – <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> may be held and <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> given without a PCC.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Elective</strong> – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Minimal bleeding</strong> – Minimal bleeding can be treated as serious bleeding (with a PCC) or as supratherapeutic INR without bleeding, depending on the perceived likelihood of more severe bleeding. (See <a class="local">'Minimal bleeding'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Without bleeding</strong> – Nonbleeding patients should <strong>not</strong> be given a PCC or FFP to correct a supratherapeutic INR. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>INR &gt;10</strong> – <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> should be held. Oral <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> (2.5 to 5 mg) can be administered, depending on bleeding risk. INR is monitored daily or every other day, and warfarin is resumed at a lower dose once the INR is therapeutic. (See <a class="local">'INR &gt;10 without bleeding'</a> above and <a class="local">'Vitamin K dose, route, formulation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>INR 4.5 to 10</strong> – <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> is held for one or two doses, with or without 1 to 2.5 mg of oral <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a>. Warfarin is resumed at a lower dose once the INR is therapeutic. (See <a class="local">'INR 4.5 to 10 without bleeding'</a> above and <a class="local">'Vitamin K dose, route, formulation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>INR &lt;4.5</strong> – One or more doses of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> may be omitted or the dose reduced slightly. If the INR elevation is minimal or expected to be transient, dose reduction may not be necessary. <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">Vitamin K</a> is not indicated. (See <a class="local">'INR &lt;4.5 without bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Poisoning</strong> – Superwarfarins can cause severe, prolonged coagulopathy. Massive <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">vitamin K</a> doses may be needed over months to years. (See <a class="local">'Superwarfarin poisoning'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-treatment evaluation</strong> – Individuals with a supratherapeutic INR should be evaluated for medication errors or metabolic changes that might have contributed. Those with gastrointestinal bleeding or hematuria will require evaluation for the bleeding source. Any individual who presents with head trauma while on <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> should be considered for neuroimaging regardless of neurologic symptoms or severity of trauma. Additional evaluations may be required for gastrointestinal bleeding, heavy menstrual bleeding, or hematuria. (See <a class="local">'Additional evaluations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resuming </strong><strong>warfarin</strong> – Anticoagulant resumption depends on thrombotic risk, bleeding site, and other risk factors for bleeding. Many patients are able to resume <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> safely. Some may be good candidates to resume anticoagulation with a direct oral anticoagulant (DOAC). (See <a class="local">'Resumption of anticoagulation after bleeding'</a> above and  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Prognosis and reinitiation of anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prosthetic heart valves</strong> – (See  <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Management of overanticoagulation without bleeding'</a>.)</p><p></p><p class="headingAnchor" id="H453729572"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Karen A Valentine, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177:347.</a></li><li><a class="nounderline abstract_t">Schelleman H, Bilker WB, Brensinger CM, et al. Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk. Am J Med 2010; 123:151.</a></li><li><a class="nounderline abstract_t">Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20:912.</a></li><li><a class="nounderline abstract_t">Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325:828.</a></li><li><a class="nounderline abstract_t">Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128:513.</a></li><li><a class="nounderline abstract_t">Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325:1073.</a></li><li><a class="nounderline abstract_t">Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105:91.</a></li><li><a class="nounderline abstract_t">Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633.</a></li><li><a class="nounderline abstract_t">Kuijer PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159:457.</a></li><li><a class="nounderline abstract_t">Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897.</a></li><li><a class="nounderline abstract_t">van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441.</a></li><li><a class="nounderline abstract_t">Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003; 163:917.</a></li><li><a class="nounderline abstract_t">Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35:2362.</a></li><li><a class="nounderline abstract_t">Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 2006; 166:853.</a></li><li><a class="nounderline abstract_t">Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713.</a></li><li><a class="nounderline abstract_t">Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357:217.</a></li><li><a class="nounderline abstract_t">Ruíz-Giménez N, Suárez C, González R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100:26.</a></li><li><a class="nounderline abstract_t">Nieto JA, Solano R, Ruiz-Ribó MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2010; 8:1216.</a></li><li><a class="nounderline abstract_t">Zhao HJ, Zheng ZT, Wang ZH, et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139:260.</a></li><li><a class="nounderline abstract_t">Hylek EM, Chang YC, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000; 160:1612.</a></li><li><a class="nounderline abstract_t">Veeger NJ, Piersma-Wichers M, Meijer K, Hillege HL. Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists. Br J Haematol 2011; 153:508.</a></li><li><a class="nounderline abstract_t">Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009; 150:293.</a></li><li><a class="nounderline abstract_t">Kucher N, Connolly S, Beckman JA, et al. International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med 2004; 164:2176.</a></li><li><a class="nounderline abstract_t">European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5.</a></li><li><a class="nounderline abstract_t">Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004; 164:668.</a></li><li><a class="nounderline abstract_t">Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348:423.</a></li><li><a class="nounderline abstract_t">Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.</a></li><li><a class="nounderline abstract_t">Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349:675.</a></li><li><a class="nounderline abstract_t">O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11.</a></li><li><a class="nounderline abstract_t">Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83:137.</a></li><li><a class="nounderline abstract_t">Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S.</a></li><li class="breakAll">http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm350239.pdf (Accessed on May 08, 2015).</li><li><a class="nounderline abstract_t">Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002; 137:884.</a></li><li><a class="nounderline abstract_t">Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003; 98:737.</a></li><li><a class="nounderline abstract_t">Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385:2077.</a></li><li><a class="nounderline abstract_t">Refaai MA, Goldstein JN, Lee ML, et al. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion 2015; 55:2722.</a></li><li><a class="nounderline abstract_t">Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2:3257.</a></li><li><a class="nounderline abstract_t">Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR&gt;10. Thromb Res 2004; 113:205.</a></li><li><a class="nounderline abstract_t">Farrow GS, Delate T, McNeil K, et al. Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio &gt; 10. J Thromb Haemost 2020; 18:1133.</a></li><li><a class="nounderline abstract_t">Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356:1551.</a></li><li><a class="nounderline abstract_t">Weibert RT, Le DT, Kayser SR, Rapaport SI. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 1997; 126:959.</a></li><li><a class="nounderline abstract_t">Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163:2469.</a></li><li><a class="nounderline abstract_t">Wilson SE, Watson HG, Crowther MA. Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 2004; 170:821.</a></li><li><a class="nounderline abstract_t">Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135:393.</a></li><li><a class="nounderline abstract_t">Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002; 137:251.</a></li><li><a class="nounderline abstract_t">Baker P, Gleghorn A, Tripp T, et al. Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol 2006; 133:331.</a></li><li><a class="nounderline abstract_t">Chirputkar SK, Poole HJ, McNeil RC, et al. Reversal of asymptomatic over-anticoagulation with oral vitamin K. Br J Haematol 2006; 135:591.</a></li><li><a class="nounderline abstract_t">Bauman ME, Black K, Bauman ML, et al. Warfarin induced coagulopathy in children: assessment of a conservative approach. Arch Dis Child 2011; 96:164.</a></li><li><a class="nounderline abstract_t">Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4:1853.</a></li><li><a class="nounderline abstract_t">Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. Thromb Haemost 2002; 88:48.</a></li><li><a class="nounderline abstract_t">Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study. Blood Coagul Fibrinolysis 2001; 12:9.</a></li><li><a class="nounderline abstract_t">Khatib R, Ludwikowska M, Witt DM, et al. Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis. Blood Adv 2019; 3:789.</a></li><li><a class="nounderline abstract_t">Ageno W, Garcia D, Silingardi M, et al. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J Am Coll Cardiol 2005; 46:732.</a></li><li><a class="nounderline abstract_t">Tummalapalli SL, Qiu Y, Cho HJ. Anticoagulation Reversal for Supratherapeutic International Normalized Ratio: A Teachable Moment. JAMA Intern Med 2017; 177:869.</a></li><li><a class="nounderline abstract_t">Banet GA, Waterman AD, Milligan PE, et al. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest 2003; 123:499.</a></li><li><a class="nounderline abstract_t">Laposata M, Van Cott EM, Lev MH. Case records of the Massachusetts General Hospital. Case 1-2007. A 40-year-old woman with epistaxis, hematemesis, and altered mental status. N Engl J Med 2007; 356:174.</a></li><li><a class="nounderline abstract_t">Bruno GR, Howland MA, McMeeking A, Hoffman RS. Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med 2000; 36:262.</a></li><li><a class="nounderline abstract_t">Weitzel JN, Sadowski JA, Furie BC, et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood 1990; 76:2555.</a></li><li><a class="nounderline abstract_t">Waien SA, Hayes D Jr, Leonardo JM. Severe coagulopathy as a consequence of smoking crack cocaine laced with rodenticide. N Engl J Med 2001; 345:700.</a></li><li><a class="nounderline abstract_t">Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol 2007; 82:656.</a></li><li class="breakAll">Outbreak alert: Potential life-threatening vitamin K-dependent antagonist coagulopathy associated with synthetic cannabinoids use. Centers for Disease Control and Prevention. April 5, 2018. https://content.govdelivery.com/accounts/USCDC/bulletins/1e6dac3.</li><li><a class="nounderline abstract_t">Schulman S, Furie B. How I treat poisoning with vitamin K antagonists. Blood 2015; 125:438.</a></li><li><a class="nounderline abstract_t">Hollinger BR, Pastoor TP. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med 1993; 153:1925.</a></li><li><a class="nounderline abstract_t">Evans SJ, Biss TT, Wells RH, Hanley JP. Emergency warfarin reversal with prothrombin complex concentrates: UK wide study. Br J Haematol 2008; 141:268.</a></li><li><a class="nounderline abstract_t">Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49:1171.</a></li><li><a class="nounderline abstract_t">Abdoellakhan RA, Khorsand N, Ter Avest E, et al. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial. Ann Emerg Med 2022; 79:20.</a></li><li class="breakAll">http://www.kcentra.com/docs/Kcentra_Prescribing_Information.pdf (Accessed on May 09, 2013).</li><li><a class="nounderline abstract_t">Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128:1234.</a></li><li><a class="nounderline abstract_t">Pagano MB, Foroutan F, Goel R, et al. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB. Transfusion 2022; 62:1652.</a></li><li><a class="nounderline abstract_t">Puchstein D, Kork F, Schöchl H, et al. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis. Thromb Haemost 2023; 123:40.</a></li><li><a class="nounderline abstract_t">Peksa GD, Mokszycki RK, Rech MA, et al. Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate. Thromb Haemost 2020; 120:207.</a></li><li><a class="nounderline abstract_t">Evans G, Luddington R, Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 2001; 115:998.</a></li><li><a class="nounderline abstract_t">Preston FE, Laidlaw ST, Sampson B, Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 2002; 116:619.</a></li><li><a class="nounderline abstract_t">Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6:622.</a></li><li><a class="nounderline abstract_t">Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106:429.</a></li><li><a class="nounderline abstract_t">Felton D, Foley EM, Traub SJ, et al. Risk of Venous Thromboembolism After Receiving Prothrombin Complex Concentrate for Warfarin-associated Intracranial Hemorrhage. J Emerg Med 2016; 50:1.</a></li><li><a class="nounderline abstract_t">Joseph R, Burner J, Yates S, et al. Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting. Transfusion 2016; 56:799.</a></li><li><a class="nounderline abstract_t">Dezee KJ, Shimeall WT, Douglas KM, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006; 166:391.</a></li><li><a class="nounderline abstract_t">Nakagawa K, Hirota Y, Sawada N, et al. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 2010; 468:117.</a></li><li><a class="nounderline abstract_t">Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e44S.</a></li><li><a class="nounderline abstract_t">Hifumi T, Takada H, Ogawa D, et al. Vitamin K2 for the reversal of warfarin-related coagulopathy. Am J Emerg Med 2015; 33:1108.e1.</a></li><li><a class="nounderline abstract_t">Li J, Brown J, Levine M. Mild head injury, anticoagulants, and risk of intracranial injury. Lancet 2001; 357:771.</a></li><li><a class="nounderline abstract_t">Brewer ES, Reznikov B, Liberman RF, et al. Incidence and predictors of intracranial hemorrhage after minor head trauma in patients taking anticoagulant and antiplatelet medication. J Trauma 2011; 70:E1.</a></li><li><a class="nounderline abstract_t">Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulated patient. Arch Intern Med 1994; 154:649.</a></li><li><a class="nounderline abstract_t">Wallis CJD, Juvet T, Lee Y, et al. Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. JAMA 2017; 318:1260.</a></li><li><a class="nounderline abstract_t">Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313:824.</a></li><li><a class="nounderline abstract_t">Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172:1484.</a></li></ol></div><div id="topicVersionRevision">Topic 1324 Version 77.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698822" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20103024" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19225037" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Kidney function influences warfarin responsiveness and hemorrhagic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12376447" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bleeding risks of antithrombotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686461" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12424167" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Oral anticoagulation and risk of death: a medical record linkage study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9727814" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782752" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074953" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172435" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk factors for intracranial hemorrhage in outpatients taking warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12435257" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12719200" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331796" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636210" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16504638" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634457" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18612534" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20345727" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285053" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10847254" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21418182" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Minor bleeds alert for subsequent major bleeding in patients using vitamin K antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258557" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505133" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776995" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037497" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8709780" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574265" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917305" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical practice. Care of patients receiving long-term anticoagulant therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15198728" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17729241" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315259" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315259" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12458988" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12691397" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25728933" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26135740" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482765" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140584" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR&gt;10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073738" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio&gt;10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11075768" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182473" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Correction of excessive anticoagulation with low-dose oral vitamin K1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609783" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993179" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560452" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186515" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16643436" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Reversal of asymptomatic over-anticoagulation by orally administered vitamin K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054668" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Reversal of asymptomatic over-anticoagulation with oral vitamin K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21068076" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Warfarin induced coagulopathy in children: assessment of a conservative approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961594" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12152676" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229833" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarine discontinuation. A prospective, randomized, open study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30850385" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098445" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418446" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Anticoagulation Reversal for Supratherapeutic International Normalized Ratio: A Teachable Moment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576372" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215536" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Case records of the Massachusetts General Hospital. Case 1-2007. A 40-year-old woman with epistaxis, hematemesis, and altered mental status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969235" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Long-acting anticoagulant overdose: brodifacoum kinetics and optimal vitamin K dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2265249" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11547737" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Severe coagulopathy as a consequence of smoking crack cocaine laced with rodenticide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17022046" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Superwarfarin poisoning: a report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17022046" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Superwarfarin poisoning: a report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25377783" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : How I treat poisoning with vitamin K antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8250654" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Case management and plasma half-life in a case of brodifacoum poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18307563" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Emergency warfarin reversal with prothrombin complex concentrates: UK wide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19210325" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34535300" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34535300" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23935011" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35834523" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36626899" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31837652" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843839" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849221" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208533" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21800002" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409668" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Risk of Venous Thromboembolism After Receiving Prothrombin Complex Concentrate for Warfarin-associated Intracranial Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26589481" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505257" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20953171" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315269" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636520" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vitamin K2 for the reversal of warfarin-related coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11253975" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mild head injury, anticoagulants, and risk of intracranial injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693913" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Incidence and predictors of intracranial hemorrhage after minor head trauma in patients taking anticoagulant and antiplatelet medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129498" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The significance of hematuria in the anticoagulated patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973248" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Association Between Use of Antithrombotic Medication and Hematuria-Related Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25710659" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987143" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
